**Final version (formally approved by the AEGIS Advisory Committee of 24.09.2010)**

|  |
| --- |
| **Template for the preparation of operational genebank manuals**  |

**Overview and general instructions for the use of the template**

In the approved document on the creation of a quality management system in AEGIS (i.e. AQUAS) the following description dealing with the development of an operational genebank manual is included: “Based on a template of an operational genebank manual, provided by the Secretariat in collaboration with the genebanks, commented by the NCGs and approved by the AEGIS Advisory Committee, will prepare a manual that contains descriptions of the routine genebank management procedures and practices and will make it available on-line (within one year from signing the Associate Membership Agreement). The elaboration of such an operational genebank manual by each associate member of AEGIS who runs a genebank and secures long- term conservation of PGR or who contributes in other ways to its effective conservation is a critical step in the establishment of a quality management system in Europe. It will provide the foundation for any collaboration between two or more genebanks as well as for any capacity building that might be required to bring the performance of a genebank to the aspired and approved standard level. This template is meant to be a tool that helps to formulate the operational genebank manual, should not be seen as a questionnaire but rather as a guide that facilitates the genebank in preparing its manual.

This draft document provides a first attempt of formulating the mentioned template. It deals with four main conservation objectives that cover the full spectrum of genebank/germplasm management:

1. Germplasm acquisition
2. Ensuring security
3. Germplasm maintenance
	1. Maintaining viability
	2. Maintaining genetic integrity
	3. Ensuring availability
4. Providing information

For each of these objectives, a set of questions are formulated that are intended to guide the curator (or whoever provides the responses) in describing the way the genebank is carrying out the routine operations at present. It has been intended to make this template applicable to seed, in vitro culture, cryopreserved and field genebank. This means that some repetition between these individual sections might occur. If you find that there are specific aspects that would not adequately fit in any of the existing sections of the current template you are kindly requested to propose a new section following the existing section where it would fit best. It should be noted that some routine operations will also contribute to one or more other objectives and that pragmatic decisions have been made where to include the operation. In instances where justified more details are provided on a routine operation that are intended as a “checklist” for the different aspects that should be addressed.

You are requested to also respond to those questions that are not applicable to your genebank by stating “n.a.”, i.e. not applicable, in order to be sure that the question has not just been forgotten.

As for a number of activities you might be referring to **protocols** that you use it would be important to either refer to a published protocol (in that case please provide a complete **literature reference**) or to include the **URL** where the protocol can be consulted, if online available. Also in cases where you or your colleagues are basing practices on long-term experiences and “traditions” it would be helpful to indicate whether and where such practices have been **described**.

As it can be foreseen that genebank manuals will require regular updating due to the dynamic circumstances we are working under it would be important to note the **date of compilation**.

The ECPGR Steering Committee agreed with the following responsibilities regarding the development of operational genebank manuals:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Secretariat**  | **Working Group** | **AEGIS Advisory Committee (AC)** | **ECPGR Steering Committee (SC)** | **Associate member** |
| **Operational genebank manual**  | Provide template, in collaboration with genebanks | Comment on the template, provided by the Secretariat | Approve the template | -  | Fill in and publish the manual  |

**0 Date of compilation**

|  |
| --- |
| **Day/month/year:**  |

**1 Germplasm Acquisition and Accessioning**

Genebanks can obtain the germplasm they want to conserve through a number of different ways. Conducting collecting missions is possibly the best way of acquiring germplasm material in the most reliable manner. Germplasm exchange with other genebanks is a third route to add genetic diversity to the collection. Obtaining and storing germplasm from researchers and plant breeders is another route to acquire genetic material. Such acquisitions should be guided by a formal mandate that the genebank concludes with its host organization or government and that provides the basis for a genebank acquisition policy. The actual accessioning of acquired germplasm samples, i.e. formally including it into the collection with its unique accession number, is a complex process during which the curator has to check a number of aspects such as the verification of the identity of the material, the health status, the availability of pertinent information, etc. It is further understood that also legal aspects form part of this activity, e.g. was the material collected/obtained in legal manner, are there any restrictions on its use, etc.

|  |
| --- |
| **Box 1.1 Germplasm Acquisition and Accessioning****GA1** - Briefly describe any formal mandate that your genebank might have concluded with or received from your “mother organization” (e.g. institute, governmental body). (*This description should include details on:* 1. *which species you conserve and make available;*
2. *who decides on what your mandate is and, if different,*
3. *from whom do you received the mandate;*
4. *the main aspects of the mandate; and*
5. *legal considerations on PGR as foreseen in national legislation).*

**GA2** – Specific agreements. Does your genebank have any specific formal agreements with other genebanks regarding the conservation of specified germplasm?(*This should include:*1. *whether or not your genebank has any international agreements to conserve specified germplasm on behalf of other countries,*
2. *a specific region, and/or*
3. *the world*), and
4. *which crops or genepools fall under these agreements?*

**GA3** -In case your genebank has a germplasm acquisition policy, what does the policy entail?. 1. *please specify which crops or which geographic area, if applicable.*

**GA4** – How do you verify the identity of the germplasm material received (e.g. relying on the donor’s information, comparing material with other accessions, involving (taxonomic) expertise, etc.)? **GA5** – Describe if and how you conduct an assessment of the various quality aspects of the seeds, tissue culture or plant material received.(*This description includes:* 1. *quality aspects related to the correct identification of a given accession, but also*
2. *health*
3. *purity aspects of the sample/accession*), and
4. *use of a quality control system (e.g. ISO).*

**GA6 –** Describe whether and how the SMTA is being implemented1. *Extent of materials covered by SMTA (crops, numbers of accessions)*
2. *Ways of SMTA implementation and documentation of transfers of PGR*
3. *Other aspects (e.g. monitoring, supervision)*
 |

|  |
| --- |
| **Box 1.2 Germplasm Collecting****GC1** – Describe here the details of the strategy that you follow in implementing germplasm collecting missions.(*This description should include:* 1. *general aspects of planning and implementing a collecting mission,*
2. *the criteria you use for priority setting;*
3. *the actual strategy followed in sampling material from farmers’ fields, from nature, etc.; and*
4. *how your germplasm acquisition policy underpins the mission*).

**SE2** – Provide any additional information on the germplasm collecting activities of your genebank, including the collaboration with others. |

**2 Ensuring Security**

 This chapter refers to the security of the genebank structure itself (i.e. its physical security), the safety of its germplasm (i.e. the maintenance of viability) as well as the institutional and personnel security, aspects which together will ensure the long-term conservation of the entire collection.

**2.1 Physical Security**

 To ensure the physical security of the collections, the following aspects are regarded as essential elements for achieving the objective:

|  |
| --- |
| **Box 2.1.1 Safety Duplication (of long-term conserved germplasm)****SD1** - Please describe how your genebank implements the safety duplication of your germplasm material. (*This description should include the following aspects:* 1. *The type of safety duplication (e.g. black-box; no specific arrangement; other);*
2. *The location(s) where you store your safety duplicates (country; genebank);*
3. *Whether or not you are using a formal agreement with the genebank(s) that store your duplicates?*
4. *Whether the safety duplicates are stored under conditions comparable to your own? Please provide details;*
5. *Do you maintain safety duplicates from other genebanks at your genebank? If so, do you know any details of that material?*)

**SD2** – Do have a safety duplication policy? If so, please provide essential details. |

|  |
| --- |
| **Box 2.1.2 Structure** **SS1** - Please provide details on how your genebank building has been designed to resist natural disasters (e.g. earthquakes; flood; storm).**SS2** - Please describe the security arrangements that you have in place to protect your genebank against burglars, fire and others. (*Please include details on the following arrangements, as applicable:* 1. *Fences;*
2. *Security doors;*
3. *Alarm system;*
4. *Fire detectors;*
5. *Standby generator;*
6. *Others (please specify*).

**SS3** – Please provide information on any other structural security aspects that you might have in place.  |

|  |
| --- |
| **Box 2.1.3 Security Equipment****SE1** - Provide details on the kind of emergency (back-up) equipment or arrangements that you have in place to ensure permanent electricity and cooling.(*Aspects to consider are:* 1. *“back-up” compressors for your cold rooms;*
2. *generator;*
3. *regular maintenance and trial runs;*
4. *other*).

**SE2** – Describe how you monitor temperature and relative humidity in your cold stores and drying room? |

|  |
| --- |
| **Box 2.1.4 Institutional and Personnel Security** **IPS1** – Provide details on the “institutional security”, in particular with respect to the provision of financial means to operate the genebank(*Aspects to consider are:* 1. *timely transfer of funds from the “mother” organization to the genebank;*
2. *do you have direct access to the “mother” organization that provides the budget?;*
3. *internal “security” of accessing these funds;*
4. *long-term security and stability of funding (compensation of inflation rates, avoiding variation in years)*
5. *any other observations that are relevant in this context)*.

**IPS2** – Describe how you secure adequate staffing of your genebank is? |

|  |
| --- |
| **Box 2.1.5 Contingency Plans**:**CP1** - Describe the kind of emergency or contingency plan that your genebank has in place to cope with disaster situations.**CP2** - Provide information on the kind of training, security drills and other activities that your genebank gives to its staff to deal with emergency situations, if any.  |

**3 Germplasm Maintenance**

This chapter deals with key aspects of managing germplasm in a genebank, i.e. the maintenance of the viability, the genetic integrity, the availability of the conserved germplasm as well as the management of the corresponding information. Given the fact we are covering seed, in vitro cultures and entire plants it might well be that not all aspects are covered by one and the same genebank. In those cases it is suggested that only the applicable sections are completed. Accordingly, at the beginning of each section of this chapter you will find a “navigation box” (highlighted in yellow) that will help you as user of the template to complete the correct section(s).

**3.1 Maintenance of Viability**

This section refers to the maintenance of the longevity of the seeds or of tissue cultures or living plants in storage. A high initial viability is the most important pre-condition for achieving the longest lifespan of seed accessions in storage, hence maximum efforts need to be taken to ensure that seeds to be stored have the highest possible viability. Optimum growing conditions when multiplying/regenerating the accessions, efficient management of the preparatory steps before storing the germplasm, adequate storage conditions as well as proper monitoring of the viability are critically important.

**Navigation Box on Maintaining Viability section**

|  |
| --- |
| **Seed** – If applicable, please complete the section on Maintaining Viability for the activities related to seed genebanks (i.e. boxes 3.1.1.A – 3.1.3.A)**In vitro cultures** – If applicable, please complete the section on Maintaining Viability for the activities related to in vitro culture (i.e. boxes 3.1.1.B – 3.1.3.B**Cryopreservation** – If applicable, please complete the section on Maintaining Viability for the activities related to cryopreserved collections (i.e. boxes 3.1.1.C – 3.1.3.C)**Field genebanks** – If applicable, please complete the section on Maintaining Viability for the activities related to field genebanks (i.e. boxes 3.1.1.D – 3.1.3.D. |

**Seed Collections**

|  |
| --- |
| **Box 3.1.1.A Initial seed viability****IV1** - Describe the procedures or practices that you have in place to ensure the highest possible initial viability of your seed, in particular during regeneration and post-harvest (e.g. cultivation practices, pollination aspects, use of specific equipment as shelters, storage of harvested seeds, cleaning, etc.).  **IV2** – Describe procedures how you deal with a) dormancy and b) hard seeds? **IV3** – Please provide any other information on procedures that you follow to ensure highest possible initial viability. |

|  |
| --- |
| **Box 3.1.2.A Seed Viability Monitoring****VM1** - Describe the routine seed viability monitoring system that you use. (*The monitoring system should include the following aspects:* 1. *frequency of testing;*
2. *sampling method applied;*
3. *any thresholds that you use;*
4. *whether you apply different procedures for crops/species with erratic initial viability or irregular viability lifespan;*
5. *etc*).

 **VM2** - Please describe the information “system” that you might have in place that allows you to make more species or even accession-specific decisions when the next monitoring should take place. **VM3** - Please provide information on non-specific thresholds that you might use for viability of seeds (i.e. percentage of germination) and for the amount of seeds left of an accession to initiate regeneration? *In case you differentiate between self- and outbreeding species, please answer for each category separately.* |

**Box 3.1.3.A Seed Storage Conditions (for the different types of collections, i.e. short/medium- or long-term storage)**

**SC1** - Please provide details on temperature and relative humidity conditions of your storage and drying rooms.In case they vary from room to room, please provide details for each.

**SC2** – Provide details on the type of containers and the packaging procedures (and the corresponding equipment, if any) that you use.

**SC3** - What is the range of seed moisture contents (smc) of your stored seeds of different species; what measures do you apply to keep and/or monitor the (low) moisture level? Do you treat different species differently?

**SC4-** Provide data on the total storage capacity (number of containers, number of accessions) and an estimated percentage to which extent this capacity has been filled.

**SC4** – Please include any other aspects regarding storage conditions at your genebank that you regard as important (e.g. anticipated lifespan of freezing and drying equipment and related prudent financial management).

1. **In vitro Culture Collections**

|  |
| --- |
| **Box 3.1.1.B Initial viability****IV1** - Describe the procedures or practices that you have in place to ensure the highest possible initial viability of your plant material, in particular during culture of donor plants (e.g. cultivation practices [field, greenhouse], phytosanitary pre-treatments, like use of pesticides).**IV2** – Describe procedures of explant isolation (organ source in the plant, manipulations) and sterilization (chemical and handling) of the explants.**IV3** – Please provide any other information on procedures that you follow to ensure highest possible initial viability. |

|  |
| --- |
| **Box 3.1.2 .B Viability Monitoring****VM1** - Describe the routine in vitro viability monitoring system that you use. (*The monitoring system should include the following aspects:* 1. *regular control of contamination events,*
2. *control of hyper-hydricity,*
3. *control of health state (if different from a above),*
4. *etc*).

 **VM2** - Describe the information “system” (i.e. an “expert system”) that you might have in place that allows you to make more species or even accession-specific decisions when the next monitoring should take place. **VM3** - Please provide information on non-specific thresholds that you might use for vigor of in vitro cultures (i. e. multiplication rates, loss by weak growth) and for the amount of culture vessels (tubes, jars) left of an accession to initiate additional multiplication measures? |

**Box 3.1.3.B Storage Conditions (for the different types of collections i.e. short/medium- or long-term storage)**

**SC1** - Please provide details on light, temperature and relative humidity conditions of your culture and storage rooms, as applicable.In case they vary from room to room, please provide details for each.

**SC2** – Provide details on the type of cultivation vessels (tubes, jars plastic vessels etc.) and the transfer procedures (including the corresponding equipment, if any) that you use.

**SC3** – Please include any other aspects regarding in vitro culture and storage conditions at your genebank that you regard as important.

1. **Cryopreserved Collections**

|  |
| --- |
| **Box 3.1.1.C Initial viability****IV1** - Describe the procedures or practices that you have in place to ensure the highest possible initial viability of your cryopreservation explant (source: in vitro pre-culture or directly from in situ explants), sterilization and explant isolation.**IV2** – Please provide any other information on procedures that you follow to ensure highest possible initial viability (e.g. elimination of virus diseases). |

|  |
| --- |
| **Box 3.1.2.C Viability Monitoring****VM1** – Please indicate whether (and if so when and how) you perform random viability tests after the initial viability test? [see also VM3 below] **VM2** - Please describe the information “system” that you might have in place that allows you to make more species or even accession-specific decisions.**VM3** – Indicate for the initial regeneration control, 1. what is the percentage of regenerated control explants relative to the total number of explants per accession;
2. any thresholds that you use [e.g. discard the material as not storable below a certain regeneration rate of the control],
3. whether you apply different procedures for accessions with erratic regeneration rates of the control [e.g. increase the amount of explants stored]; etc. and
 |

**Box 3.1.3.C Storage Conditions (for the different types of collections i.e. short/medium- or long-term storage)**

**SC1** - Please provide information on the general system used for cryopreservation (liquid nitrogen or vapor phase, automatic tank filling or filling by hand).In case they vary from tank to tank, please provide details for each.

**SC2** – Provide details on the type of cryopreservation tanks and storage system within the tank that you use.

**SC3** - Do you treat different species differently?

**SC4** – Please include any other aspects regarding storage conditions at your genebank that you regard as important.

1. **Field Genebank Collections**

|  |
| --- |
| **Box 3.1.1.D Initial viability****IV1** - Describe the procedures or practices that you have in place to ensure the highest possible quality of your planting material, in particular during the growing from donor plants (e.g. cultivation practices in the field or greenhouse], phytosanitary pre-treatments, etc.).**IV2** – Describe any particular procedures you use (e.g. which organ of the donor plant you use to reproduce the planting material).**IV3** – Please provide any other information on procedures that you follow to ensure highest possible initial quality. |

|  |
| --- |
| **Box 3.1.2 .D Viability Monitoring****VM1** - Describe the routine field genebank monitoring system that you use. (*The monitoring system could include the following aspects: regular control of disease or pest contamination, other types of damages to the plants, etc*). **VM2** - Describe the information “system” that you might have in place that allows you to make more species or even accession-specific decisions when the next monitoring should take place. **VM3** - Please provide information on non-specific thresholds that you might use for the quality of the individual plants (e.g. loss by weak growth) and for the amount of plants of an accession left in the field before additional initiating multiplication measures? |

**Box 3.1.3.D Maintenance Conditions**

**SC1** - Please provide details on your cultural practices (e.g. cultivation practices; pruning; irrigation; protection against animals etc.; pest and disease management; etc. applied to your field genebank material.

**SC2** – In the case of annual or sub-perennial species that cannot over-winter in the field genebank, what measures do you take?

**SC3** – Please include any other aspects regarding field genebank maintenance conditions at your genebank that you regard as important.

**3.2 Maintaining Genetic Integrity**

Maintaining the genetic integrity of an accession can be achieved by minimizing genetic drift which may occur predominantly during the process of regeneration, due to too small numbers of individuals being planted, sub-optimal pollination and/or the introgression of alleles from other accessions or commercial crops or crop wild relatives. The following aspects are important and for achieving the objectives of maintaining genetic integrity and should be briefly described. Please note that a distinction should be made between seed numbers for an accession and seed numbers for sub-samples per accession. The latter only applies if the seeds of a given accession are being stored and distributed as sub-samples. As genetically modified materials get more widely distributed and as it might have specific (legal, technical, administrative) requirements a separate box on this type of material is included.

For in vitro cultured and cryopreserved material, which are normally maintained as clones, genetic stability is as important as genetic integrity of the seed-stored material.

**Navigation Box on Maintaining Genetic Integrity section**

|  |  |
| --- | --- |
|

|  |
| --- |
| **Seed** – If applicable, please complete the section on Genetic Integrity for the activities related to seed genebanks (i.e. boxes 3.2.1.A – 3.2.5.A)**In vitro cultures** – If applicable, please complete the section on Genetic Integrity for the activities related to in vitro culture (i.e. boxes 3.2.1.B – 3.2.3.B**Cryopreservation** – If applicable, please complete the section on Genetic Integrity for the activities related to cryopreserved collections (i.e. boxes 3.2.1.C – 3.2.3.C)**Field genebanks** – If applicable, please complete the section on Genetic Integrity for the activities related to field genebanks (i.e. boxes 3.2.1.D – 3.2.3.D  |

 |

**A. Seed Collections**

|  |
| --- |
| **Box 3.2.1.A Seed Containers and Sample Size** **SCSS1** – Do you document the initial number of seeds of individual accessions (either as received from collecting missions or through exchange)? **SCSS2** – Please describe what kind of containers (and equipment) you use, the procedure you follow with respect to sub-sampling, seed numbers per container, etc. **SCSS3** - What is the number of seeds that you use as the minimum threshold per accession? Are these seed numbers of a given accession based on genetic parameters (such as reproduction biology; heterogeneous samples)? Please provide URL of your protocols if these are on-line available **SCSS4** – Please provide details on other aspects that are important in this context. |

|  |
| --- |
| **Box 3.2.2.A Pollination Control** **PC1** - Please describe the regeneration procedures that you follow for self- and outbreeding species. (*Please include in your description the following aspects:*1. *Any control measures to minimize or avoid cross pollination between accessions;*
2. *The use of pollination cages for insect pollinated species;*
3. *The use of specific pollinators for insect pollinated species;*
4. *Strategies to ensure that males and females participate equally in the reproduction*).
5. *Strategies to avoid any genetic drift (minimum number of plants, minimum number of plants at flowering stage before pollinators introduction, similar quantity of seeds harvested from each plant, etc.)*

**PC2** – Provide any other relevant information on procedures that you apply to control pollination of your germplasm. |

|  |
| --- |
| **Box 3.2.3.A Regeneration Environment and Procedures****RE1** – Describe the regeneration environment and conditions that you apply. If applicable, you might want to distinguish between different types of germplasm (e.g. wild relatives, landraces, modern varieties, breeding material, genetic stocks, etc.).(*Consider the following aspects:* 1. *In how far are the environmental conditions of the current regeneration of individual germplasm accessions comparable to the environmental conditions that existed at the original collecting or breeding site?;*
2. *Do you use controlled environments?;*
3. *Do you collaborate with other genebanks in Europe?;*
4. *others*).

**RE2** – Please include any other relevant points on regeneration environment. |

|  |
| --- |
| **Box 3.2.4.A Seed Processing Procedures** **SPP1** – Describe the protocol(s) that you use for threshing and seed cleaning. .**SPP2** – Describe the protocol(s) that you use for seed drying, including whether you use different drying procedures for different types of species. **SPP3** – Please describe how you keep the time between harvesting and the actual (long-term) storage of seeds as short as possible.**SPP4** – Please describe how and where you store (in a temporary manner) newly harvested seeds.(Please provide details on the temperature and relative humidity of the storage room/space; what type of containers do you use, if any).**SPP5** – Describe the criteria you use to decide on seed quantity per accession for the long-term storage. |

|  |
| --- |
| **Box 3.2.5.A Genetically Modified Material** **GMM1** – In case you treat GMO material differently from “normal germplasm”, please provide here the details for each of the deviating procedures (and equipment). **GMM2** – Describe the policy and procedures (if any) in your genebank, related to ensuring that distributed samples are not containing GMOs.  |

**B. In vitro Culture Collections**

|  |
| --- |
| **Box 3.2.1.B In vitro Culture Vessels and Sample Size** **SCSS1** – Indicate if you document the initial number of explants of individual accessions when culture is initiated (from one or from more clonal donor plants)? **SCSS2** – Please describe in general terms the type of culture vessels (as far not already done in section SC2 in Box 3.1.3.B), media and phytohormones you use as well as the procedures you follow with respect to cutting technique, callus exclusion, etc. **SCSS3** – Please indicate whether or not you use a minimum number of in vitro plantlets per accession? **SCSS4** – Please provide details on other aspects that are important in this context. |

|  |
| --- |
| **Box 3.2.2.B In vitro Culture Procedures** **SPP1** – Describe the numbers of sub-clones you may cultivate per accession (assuming that this is not crop specific)**SPP2** – Describe the sub-culture duration (if not crop specific)**SPP3** – Describe the criteria you use to decide on in vitro plant quality (if not crop specific). |

|  |
| --- |
| **Box 3.2.3.B Genetically Modified Material** **GMM1** – In case you treat GMO material differently from “normal germplasm”, please provide here the details for each of the deviating procedures (and equipment). |

**C. Cryopreserved Collections**

|  |
| --- |
| **Box 3.2.1.C Cryopreservation Containers and Sample Size** **SCSS1** – Indicate if you document the initial number of explants of individual accessions?**SCSS2** – Please describe what kind of cryopreservation vessels (and equipment) you use (only if they differ from the corresponding answers in previous boxes), the procedure you follow with respect to separate material containing viruses or bacteria from healthy material **SCSS3** - What is the number of explants that you use as the minimum threshold per accession? **SCSS4** – Please provide details on other aspects that are important in this context. |

|  |
| --- |
| **Box 3.2.2.C Cryopreservation Procedures (as long as not crop specific)****SPP1** – Describe the protocol(s) that you use for preculture and pretreatment such as cold acclimation and dehydration.**SPP2** – Describe the protocol(s) that you use for cryopreservation proper (such as slow freezing, droplet freezing, vitrification, encapsulation etc.)**SPP3** – Describe the protocols that you use for regeneration (slow or fast rewarming, washing, dark periods etc.)**SPP4** – Describe the time span and method(s) of survival and regeneration controls**SPP5** – Describe the criteria you use to decide on explant quantity per accession for the long-term storage. |

|  |
| --- |
| **Box 3.2.3.C Genetically Modified Material** **GMM1** – In case you treat GMO material differently from “normal germplasm”, please provide here the details for each of the deviating procedures (and equipment). |

1. **Field Genebank Collections**

|  |
| --- |
| **Box 3.2.1.D Accession Sample Size** **SCSS1** – Indicate if you document the initial number of plants of individual accessions (either as received from collecting missions or through exchange)? **SCSS2** – Please describe what kind of procedures you follow, if any, with respect to sub-sampling and subsequent place/container/etc. of maintenance?**SCSS3** - What is the number of plants that you use as the minimum threshold per accession? Are these plant numbers of a given accession based on genetic parameters (such as reproduction biology; heterogeneous samples)?**SCSS4** – Please provide details on other aspects that are important in this context. |

|  |
| --- |
| **Box 3.2.2.D Multiplication** **PC1** - Please describe the multiplication procedures that you follow for your field genebank material (both, annual as well as perennial species)? (*Please include in your description the following aspects if they would apply to your field genebank management procedures): :*1. *Any control measures to minimize or avoid cross pollination between accessions (if applicable/relevant);*
2. *The use of pollination cages for insect pollinated species;*
3. *The use of specific pollinators for insect pollinated species;*
4. *Strategies to ensure that males and females participate equally in the reproduction*).
5. *Strategies to avoid any genetic drift (minimum number of plants, minimum number of plants at flowering stage before pollinators introduction, similar quantity of seeds harvested from each plant, etc.)*

**PC2** – Provide any other relevant information on procedures that you apply to control pollination of your germplasm in case of harvesting planting material from your field genebank material? |

|  |
| --- |
| **Box 3.2.3.D Planting Material Processing Procedures** **SPP1** – Describe the protocol(s) that you use for threshing and seed cleaning, if used as an intermediate step for the management/multiplication of your field genebank accessions .**SPP2** – Please describe how and where you store (in a temporary manner) newly harvested planting material.(Please provide details on the temperature and relative humidity of the storage room/space; what type of containers do you use, if any, etc.).**SPP3** – Describe the criteria you use to decide on the number of plants per accession intended for the long-term conservation. |

**3.3 Ensuring Availability**

An important objective of conservation efforts is to facilitate the effective utilization of germplasm accessions by researchers, breeders and farmers. Thus, ensuring the ready availability of stored germplasm is an important principle. It refers to the ability of genebanks to supply and distribute the stored germplasm, together with any associated information, in an adequate way to users. Aspects that can affect the availability include: (a) policies, (b) seed stock, (c) health status of accessions, and (d) distribution quantity. Although most of the questions are not relevant in the ECPGR/AEGIS context, it was decided to keep the questions and to allow for a comprehensive genebank manual that can be used “globally”.

**Navigation Box on Ensuring Availability**

|  |
| --- |
| **Seed** – If applicable, please complete the section on Ensuring Availability for the activities related to seed genebanks (i.e. boxes 3.3.1.A – 3.3.4.A)**In vitro cultures** – If applicable, please complete the section on Ensuring Availability for the activities related to in vitro culture (i.e. boxes 3.3.1.B – 3.3.4.B**Cryopreservation** – If applicable, please complete the section on Ensuring Availability for the activities related to cryopreserved collections (i.e. boxes 3.3.1.C – 3.3.4.C)**Field genebanks** – If applicable, please complete the section on Ensuring Availability for the activities related to field genebanks (i.e.boxes 3.3.1.D – 3.3.4.D  |

1. **Seed Collections**

|  |
| --- |
| **Box 3.3.1.A Ensuring Availability of Germplasm – Policy Aspects****AGP1** – Describe the germplasm distribution policy that you follow at your genebank. (*You might want to consider in your response the following aspects:*1. *crop/species specificity;*
2. *whether or not sufficient seed stock is available; who the requestor is;*
3. *what the purpose of the germplasm request is;*
4. *any restrictive conditions and/or*
5. *the total amount of accessions sent per request for distribution of germplasm;*
6. *use of a formal agreement to distribute the germplasm*).

**AGP2** - Do you have as part of your service rendering policy aspects such as a “maximum time” between receiving a germplasm request and distribution of the germplasm?**AGP3** – Describe how you treat “related information” about the requested accessions that you make available to the requestor, i.e. provide details on the typical information you send out with the germplasm*.*  |

|  |
| --- |
| **Box 3.3.2.A Ensuring Availability of Germplasm – Seed/Germplasm Stock Aspects****AGSS1** - Please provide details on the minimum/maximum amount of seed, plant, in vitro samples that you distribute (where relevant, differentiated by species groups, i.e. self-pollinating, cross-pollinating and/or whether an accession is homo- or heterogeneous).**AGSS2** – Describe how you store the seeds/etc. of a given accession with respect to the use of single or multiple bags or containers per accession. **AGSS3** – Describe how you manage the availability of adequate seed/etc. stock per accession, including the use of an absolute lower minimum of seeds per accession as the threshold to decide to regenerate. **AGSS4** – Provide here information on any other aspects that are relevant to manage seed/etc. stocks. |

|  |
| --- |
| **Box 3.3.3.A Ensuring Availability of Germplasm – Health Aspects****AGHA1** – Describe how you store seed/other germplasm with respect to germplasm health considerations, including whether you have a “policy” of storing only “disease free” (as far as you can see or determine) accessions, at least for the quarantine pests and diseases.**AGHA2** – Describe how you follow plant quarantine rules and regulations when exporting germplasm abroad (especially to countries at another continent). **AGHA3** – Describe if and how you distribute germplasm accompanied by a phytosanitary certificate or a “plant passport”. **AGHA4** – Provide any other relevant information on procedures that you follow with respect to germplasm health aspects. |

|  |
| --- |
| **Box 3.3.4.A Germplasm Supply****GS1** – Describe the policy of your genebank with respect to the sample size that you use for distribution purposes, including whether you differentiate between germplasm from self- or outbreeding species, heterogeneous accessions, and possibly other aspects.**GS2** – As GS1 above, but in case your germplasm samples do not possess the minimum viability, would you increase the number of seeds?**GS3** – Please provide information on any other aspects related to seed supply. |

1. **In vitro Culture Collections**

|  |
| --- |
| **Box 3.3.1.B Ensuring Availability of Germplasm – Policy Aspects****AGP1** – Describe the germplasm distribution policy that you follow at your genebank. (*You might want to consider in your response the following aspects: is the user informed about the option to get provided with in vitro cultures and whether they are available all the time of the year, are in vitro samples an option or the only way to get material; who the requestor is; what the purpose of the germplasm request is; any restrictive conditions and/or the total amount of accessions sent per request for distribution of germplasm; use of a formal agreement to distribute the germplasm)***AGP2** – Indicate if you have as part of your service rendering policy aspects such as a “regular or a maximum time” between receiving a germplasm request and distribution of the germplasm?**AGP3** – Describe how you treat “related information” about the requested accessions that you make available to the requestor, i.e. provide details on the typical information you send out with the germplasm*.*  |

|  |
| --- |
| **Box 3.3.2.B Ensuring Availability of Germplasm – Germplasm Stock Aspects****AGSS1** - Please provide details on the maximum amount of in vitro samples that you distribute.**AGSS2** – Describe how you store the samples of a given accession with respect to the use of vessels for culture and vessels for distributions (glasses of plastic bags).**AGSS3** – Describe how you manage the availability of adequate plants per accession, including the use of an absolute lowest minimum of plants per accession as the threshold to decide to regenerate. **AGSS4** – Provide here information on any other aspects that are relevant to manage stocks (e.g. transfer of material through greenhouse transfer phases in case a user cannot handle in vitro cultures). |

|  |
| --- |
| **Box 3.3.3.B Ensuring Availability of Germplasm – Health Aspects****AGHA1** – Describe how you store germplasm with respect to germplasm health considerations, including whether you have a “policy” of storing only “disease free” (as far as you can see or determine) accessions, at least for the quarantine pests and diseases.**AGHA2** – Describe how you follow plant quarantine rules and regulations when exporting germplasm abroad (especially to countries at another continent). **AGHA3** – Describe if and how you distribute germplasm accompanied by a phytosanitary certificate or a “plant passport”. **AGHA4** – Provide any other relevant information on procedures that you follow with respect to germplasm health aspects. |

|  |
| --- |
| **Box 3.3.4.B Germplasm Supply****GS1** – Describe the policy of your genebank with respect to the sample size that you use for distribution purposes.**GS2** – Please provide details of your routine methodology of containers etc. that you use to distribute in vitro cultures.**GS3** – Please provide information on any other aspects related to in vitro plant supply. |

1. **Cryopreserved Collections**

|  |
| --- |
| **Box 3.3.1.C Ensuring Availability of Germplasm – Policy Aspects****AGP1** – Describe the germplasm distribution policy that you follow at your genebank. (*Cryopreserved material is for distribution in exclusive cases only – e.g. for special research, please describe your policy*; *who the requestor is; what the purpose of the germplasm request is; any restrictive conditions and/or the total amount of accessions sent per request for distribution of germplasm; use of a formal agreement to distribute the germplasm*).**AGP2** – Indicate if you have as part of your service rendering policy aspects such as a “regular or maximum time” between receiving a germplasm request and distribution of the germplasm?**AGP3** – Describe how you treat “related information” about the requested accessions that you make available to the requestor, i.e. provide details on the typical information you send out with the germplasm*.*  |

|  |
| --- |
| **Box 3.3.2.C Ensuring Availability of Germplasm – Germplasm Stock Aspects****AGSS1** - Please provide details on samples that you distribute (where relevant).**AGSS2** – Describe how you store, for distribution, the cryopreserved material of a given accession with respect to the use special equipment such as dry-shippers etc. **AGSS3** – Describe how you manage the availability of adequate cryopreserved material.**AGSS4** – Provide here information on any other aspects that are relevant to manage seed/etc. stocks. |

|  |
| --- |
| **Box 3.3.3.C Ensuring Availability of Germplasm – Health Aspects****AGHA1** – Describe how you store seed/other germplasm with respect to germplasm health considerations, including whether you have a “policy” of storing only “disease free” (as far as you can see or determine) accessions, at least for the quarantine pests and diseases. You could also add data on separation of differently infested material in separate cryotanks etc.**AGHA2** – Describe how you follow plant quarantine rules and regulations when exporting germplasm abroad (especially to countries at another continent). **AGHA3** – Describe if and how you distribute germplasm accompanied by a phytosanitary certificate or a “plant passport”. **AGHA4** – Provide any other relevant information on procedures that you follow with respect to germplasm health aspects. |

|  |
| --- |
| **Box 3.3..C4 Germplasm Supply****GS1** – Describe the policy of your genebank with respect to the sample size that you use for distribution purposes.**GS2** – Please provide details of your routine methodology of containers etc. that you use to distribute cryopreserved material.**GS3** – Please provide information on any other aspects related to cryopreserved material supply. |

1. **Field Genebank Collections**

|  |
| --- |
| **Box 3.3.1.D Ensuring Availability of Germplasm – Policy Aspects****AGP1** – Describe the germplasm distribution policy that you follow at your genebank. (*You might want to consider in your response the following aspects: crop/species specificity; whether or not sufficient seed stock is available; who the requestor is; what the purpose of the germplasm request is; any restrictive conditions and/or the total amount of accessions sent per request for distribution of germplasm; use of a formal agreement to distribute the germplasm*).**AGP2** – Indicate if you have as part of your service rendering policy aspects such as a “maximum time” between receiving a germplasm request and distribution of the germplasm?**AGP3** – Describe how you treat “related information” about the requested accessions that you make available to the requestor, i.e. provide details on the typical information you send out with the germplasm*.*  |

|  |
| --- |
| **Box 3.3.2.D Ensuring Availability of Germplasm – Seed/Germplasm Stock Aspects****AGSS1** - Please provide details on the minimum/maximum amount of plants or organs (cuttings, bulbs, tubers, etc.) per plant that you distribute per accession (where relevant, differentiated by species groups, i.e. annual or perennial; woody or herbaceous; other) and/or whether an accession is clonally or sexually propagated).**AGSS2** – Describe how you manage the availability of adequate organs per accession, including the use of an absolute lower minimum of plants per accession as the threshold to decide to multiply. **AGSS3** – Provide here information on any other aspects that are relevant to manage plant material stocks. |

|  |
| --- |
| **Box 3.3.3.D Ensuring Availability of Germplasm – Health Aspects****AGHA1** – Describe how you maintain field genebank (and any intermediate storage step) accessions with respect to health considerations, including whether you have a “policy” on accepting/planting only “disease free” planting material (as far as you can see or determine) accessions, at least for the quarantine pests and diseases.**AGHA2** – Describe how you follow plant quarantine rules and regulations when exporting germplasm abroad (especially to countries at another continent). **AGHA3** – Describe if and how you distribute germplasm accompanied by a phytosanitary certificate or a “plant passport”. **AGHA4** – Provide any other relevant information on procedures that you follow with respect to germplasm health aspects. |

|  |
| --- |
| **Box 3.3.4.D Germplasm Supply****GS1** – Describe the policy of your genebank with respect to the sample size that you use for distribution purposes, including whether you differentiate between germplasm from annual or perennial species, clonally or sexually propagated accessions, and possibly other aspects.**GS2** – Please provide information on any other aspects related to seed supply. |

**4 Providing Information**

The lack of adequate information on a given accession may well decrease the value of that accession to the user. The information on individual accessions should be as complete as possible in order to facilitate the identification of duplicates and/or to select accessions with desirable characteristics. A genebank should have a documentation system in place that allows to optimize management of the collections as well as to provide access to information about the collection to users.

|  |
| --- |
| **Box 4.1 Genebank Documentation System****GD1** - Please provide details on the technical aspects of the genebank information management system(s) that you use. 1. On which software is the system based (i.e. Oracle, Fox Pro, MS Access, MS excel, MS Word, other?).
2. In case you use a manual information management system, please provide details.
3. In case your “internal” database(s) is/are different from the publicly available database(s), please provide details on both,
4. Describe which activities of the genebank are covered by the system.

**GD2** - Provide details on which types of data you handle in your documentation system, e.g. passport data, characterization & evaluation data, cultivar data, material distribution etc. **GD3** - In case your internal database(s) is/are different from the publicly available database(s), please provide details on both.**GD4** – Describe in which form you send accession specific data (e.g. as hard copy, electronically – if the latter, please specify (in plain text) which file format, i.e. Excel, Access, others is used). **GD5 -** Provide information on how technical support for development and maintenance of the documentation system is arranged**GD6** – Describe your genebank policy with respect to backing-up of the database contents, including with which frequency?**GD7** – Provide any other information on your information management system that is not covered in one of the above questions. |

|  |
| --- |
| **Box 4.2 Information Exchange****IE1** – Please describe how you make your passport data available to users (i.e. as hard copy; via the internet; other?).**IE2 -** Please indicate if your data is available as machine to machine web-services. In case it is, describe 1. what types of data (passport data, characterization & evaluation data etc) and
2. which web-service interfaces are available (i.e. GBIF IPT, BioCase, TapirLink).

**IE3** - Please indicate if your data is published to EURISCO. Describe which data is published to EURISCO and at which intervals.**IE4** – Please provide any other information on information exchange that is important for others to know.**IE5** - Describe the kind of information you distribute together with the germplasm to persons that request germplasm?(*Please consider the following data types: Passport, Characterization; Evaluation, and/or Germplasm management data (e.g. viability percentage; protocols followed for routine operations; etc.*). |

Thank you for the efforts you have made to answer all the questions. This information will be important to you and your colleagues at the genebank as well as to the Working Groups and other bodies in ECPGR for the establishment of a quality genebank management system!

The ECPGR Secretariat